Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLR1 siRNA
- Development stage
- Preclinical
- Lead developer
- Eisai
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
FOLR1 siRNA is a small interfering RNA (siRNA) designed to silence the expression of the FOLR1 gene, which encodes Folate Receptor Alpha (FRα). FRα is a glycosylphosphatidylinositol-anchored protein that is frequently overexpressed in epithelial malignancies, such as ovarian and renal cell carcinomas, while remaining largely absent in normal tissues. Research conducted by Morphotek demonstrated that siRNA-mediated knockdown of FOLR1 significantly impairs the proliferative capacity of cancer cells, even in cisplatin-resistant models. These findings suggest that FRα promotes tumor growth through mechanisms that may be independent of its canonical role in folate transport, making it a critical target for therapeutic intervention.
- Other names
- FRα siRNAfolate receptor alpha siRNA
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on FOLR1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLR1 siRNA.